Legal Representation
Attorney
Scott D. Woldow
USPTO Deadlines
Next Deadline
1969 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2024-12-03)
Due Date
December 03, 2030
Grace Period Ends
June 03, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
26 events| Date | Code | Type | Description |
|---|---|---|---|
| May 24, 2025 | FINO | P | FINAL DECISION TRANSACTION PROCESSED BY IB |
| May 6, 2025 | FIMP | P | FINAL DISPOSITION PROCESSED |
| May 6, 2025 | FICS | P | FINAL DISPOSITION NOTICE SENT TO IB |
| Apr 4, 2025 | OPNX | P | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB |
| Mar 18, 2025 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Mar 18, 2025 | OPNR | P | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB |
| Mar 3, 2025 | FICR | P | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| Dec 3, 2024 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| Dec 3, 2024 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
| Oct 1, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Oct 1, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Sep 11, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Aug 27, 2024 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Aug 27, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Aug 27, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Aug 27, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Jun 3, 2024 | RFNP | P | REFUSAL PROCESSED BY IB |
| May 16, 2024 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| May 16, 2024 | RFRR | P | REFUSAL PROCESSED BY MPU |
| May 7, 2024 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| May 6, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN |
| Apr 30, 2024 | DOCK | D | ASSIGNED TO EXAMINER |
| Feb 16, 2024 | PARI | I | TEAS VOLUNTARY AMENDMENT RECEIVED |
| Oct 24, 2023 | MAFR | O | APPLICATION FILING RECEIPT MAILED |
| Oct 20, 2023 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Oct 19, 2023 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB |
Detailed Classifications
Class 005
Pharmaceutical preparations for cardiovascular diseases, illnesses, and conditions; Pharmaceutical preparations for infusion conditions; pharmaceutical preparations for cardiovascular conditions and blood conditions, namely, novel, plasma derived apolipoprotein A-I conditions while undergoing infusion therapy; pharmaceutical preparations for novel apolipoprotein A-I infusion therapy to potentially reduce the risk of recurrent major adverse cardiovascular events (MACE) in patients within 90 days of an acute myocardial infarction (AMI) with a sustained benefit for 365 days; Pharmaceutical preparations for acute myocardial infarction (AMI); Pharmaceutical preparations for cardiovascular diseases; pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; pharmaceutical preparations and substances for the treatment of blood disorders; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE; Pharmaceutical preparations, namely, for the treatment of Hereditary Angioedema, HAE, respiratory diseases, acute respiratory distress syndrome, ARDS, Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD
Classification
International Classes
005
USPTO Documents
Click to view cached USPTO documents for this trademark
Only administrators can request new documents from USPTO